Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments
NGN-PET logo


Start Date
End Date
IMI2 - Call 7
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
1 500 000
EFPIA in kind
1 550 000
Total Cost
3 050 000


Neuropathic pain is a chronic condition affecting around 8 % of the population. It can be triggered in various ways, including through surgery, injury, diabetes, chemotherapy, and viral infection. Existing treatments are only effective in a minority of patients. Furthermore, treatments address the symptoms, not the underlying causes of the pain, and so are not curative. In fact, the underlying causes of neuropathic pain are still poorly understood, and that’s where the NGN-PET project comes in.

The NGN-PET team will focus its efforts on interactions between nerve cells (neurons) and glial cells (also known as glia). There are many types of glia, and their role in the nervous system includes supporting nerve cells, insulating them, and providing them with nutrients and oxygen. Recent research has revealed that glial cells are actively involved in the development of sensory abnormalities, including pain.

NGN-PET aims to explore neuron-glial interactions in neuropathic pain caused by chemotherapy or trauma by developing advanced neuron-glia cell cultures based on induced pluripotent stem cells (iPSCs). The outcome of the project will be a high throughput screening platform that can then be used to rapidly test potential treatments and will ultimately pave the way for the development of safe, effective pain treatments.

Participants Show participants on map

EFPIA companies
  • Esteve Pharmaceuticals, SA, Barcelona, Spain
  • Grunenthal GMBH, Aachen, Germany
Universities, research organisations, public bodies, non-profit groups
  • King'S College London, London, United Kingdom
  • Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Axxam S.A, Bresso (Milan), Italy
  • Life And Brain GMBH, Bonn, Germany
Project leader
Xavier Codony
Project management
Enric Castells, Esteve
Project e-mail